Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, has officially launched the expansion of its production line at its Bray facility.
The company which has been established in Bray since 1997 currently employs more than 340 employees at the Co. Wicklow facility in which it has invested €20m over the past two years.
The expansion announced this week allows for the addition of production, packaging and shipping of two oncology products to the site’s manufacturing portfolio, with Oncology production being a new therapeutic area for the Bray site. Commercial production of the first of these products will start at the end of 2020.
Takeda Ireland – Bray, was established in 1997 as a Solid Oral Dosage Facility, which produces, packs and ships granulates, solid oral dosage tablets and final packaged products to the worldwide markets including the major US, European, Japanese and valuable emerging markets.
As of today, Bray produces products for the therapeutic areas of Cardiovascular and Metabolic, Central Nervous System (CNS), Gastrointestinal and Oncology.
Speaking this week, Bray Site Head at Takeda Ireland, James Dinniss said, "Over the past two and half years the teams have demonstrated their experience, perseverance and flexibility to deliver this complex project on time and budget through many challenges, not least the COVID pandemic."
He added, "We are very excited to start production of these Oncology products for patients who currently have limited options for treatments, and we are proud that the products we make will have a significant impact on their life."